Summary slide.png (119.37 kB)

Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra®) in the Republic of Korea, 2014–2019

figure

posted on 2021-01-08, 13:26 authored by Hee Soo Kim, Solene Engel, David Neveu, Yael Thollot, Philipp Oster, Kuhyun Yang

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s40121-020-00393-4

Usage metrics

Read the peer-reviewed publication

Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra®) in the Republic of Korea, 2014–2019

Infectious Diseases and Therapy

Keywords

Adverse reactions or events Menactra®MenACWY-DT, MCV4 Meningococcal infections Meningococcal vaccine Safety Vaccines

Licence

CC BY-NC 4.0

Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra®) in the Republic of Korea, 2014–2019

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports